NCT06474013View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Initial Safety and Efficacy of Repetitive BBB (Blood Brain Barrier) Disruption Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Alzheimer's Disease

NANot yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

July 31, 2025

Conditions
Alzheimer Disease
Interventions
DEVICE

ExAblate 4000 Type 2.1

The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.1 system, and this will be performed 3 times every 2 months.

All Listed Sponsors
lead

Korea University Anam Hospital

OTHER

NCT06474013 - A Clinical Trial to Evaluate the Initial Safety and Efficacy of Repetitive BBB (Blood Brain Barrier) Disruption Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter